GU CONNECT expert, Prof. Gert Attard provides a GU cancer update from ESMO 2020 for you.


GU cancer update by Prof. Gert Attard, University College London Cancer Institute, UK

 

Prof. Attard is a Cancer Research UK Clinician Scientist and Team Leader at The Institute of Cancer Research and an Honorary Medical Oncology Consultant at the Royal Marsden NHS Foundation Trust, London, UK. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration-resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 100 peer-reviewed manuscripts, including several important papers on advanced prostate cancer. Prof. Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. Prof. Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.

Prof. Gerhardt Attard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Grants or contracts from Astellas Pharma, Blue Earth Therapeutics, Janssen, Veracye and Novartis

 

Consulting fees from Amgen, AstraZeneca, Astellas Pharma, Bayer, Blue Earth Therapeutics, Janssen-Cilag, Merck & Co, Merck Sorono Ltd, Novartis, Pfizer, Veracyte.

 

Payment or honoraria from Astellas Pharma, Janssen, Astrazeneca, Sanofi, Sandoz.

 

Support for attending meetings/travel from Amgen, Astellas Pharma, Bayer, Janssen, Merck Sorono Ltd, Pfizer

 

On the Institute of Cancer Research Discoveries list of abiraterone acetate. Listed as inventor on docetaxel predictive, biomarker (Veracyte).

 

Listed as inventor on patent related to blood biomarkers (UCL, Cancer Research Horizons)

 

Commercial agreements with employer, UCL with Artera and Veracyte

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update

Episode

3

of 3

episode
Oncology 
How are new data shaping the landscape in HER2-mutant NSCLC?

Insights from WCLC 2026

Experts
Dr Joshua Sabari
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • clock 5 MIN
  • calendar Sep 2026

Educational programme supported by an Independent Educational Grant from Bayer.
blueprint BluePrintInfographic / Flashcard
Oncology 
Biomarker testing in non-small cell lung cancer (NSCLC)

Insights from patients and caregivers

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr Rodrigo Paredes de la Fuente, Anne-Marie Baird, Amy C. Moore, Shani Shilo
Endorsed by
LUNGevity The Israeli Lung Cancer Foundation
Biomarker Collaborative NTRKers Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology Hemato-oncology 
Myelofibrosis: Navigating unmet needs and overcoming clinical challenges

Expert perspectives on clinical trial highlights from EHA 2026

Experts
Prof. Francesco Passamonti, Prof. Claire Harrison
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jul 2026

Brought to you by COR2ED Medical Affairs in collaboration with Menarini Stemline. This programme is intended for HCPS outside the UK. MED---2600258
micro-learning Micro learning - Video, slides and more
Oncology 
The evolving treatment landscape in HER2-mutant NSCLC

Expert insights on how the latest evidence is shaping clinical practice

Experts
Dr Devika Das, Dr Tom Newsom-Davis
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer